Oragenics Inc. Files Q2 2024 10-Q Report
Ticker: OGEN · Form: 10-Q · Filed: Aug 9, 2024 · CIK: 1174940
| Field | Detail |
|---|---|
| Company | Oragenics INC (OGEN) |
| Form Type | 10-Q |
| Filed Date | Aug 9, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Oragenics filed its Q2 10-Q. Financials updated.
AI Summary
Oragenics Inc. filed its 10-Q for the period ending June 30, 2024. The company, based in Sarasota, Florida, operates in the pharmaceutical preparations sector. The filing covers the second quarter of 2024 and provides financial data as of June 30, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with the latest financial performance and position of Oragenics Inc., crucial for understanding the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (10-Q) and does not inherently present new risks.
Key Numbers
- 2024-06-30 — As of Date (End of reporting period for financial statements.)
- 2023-12-31 — Prior Year End Date (Comparison point for financial data.)
Key Players & Entities
- ORAGENICS INC (company) — Filer
- 20240630 (date) — Period of Report
- 20240809 (date) — Filing Date
- SARASOTA (location) — Company Headquarters City
- FL (location) — Company Headquarters State
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240809.
What is the primary business of Oragenics Inc. according to the filing?
Oragenics Inc. is classified under Pharmaceutical Preparations [2834].
Where is Oragenics Inc. headquartered?
Oragenics Inc. is headquartered in Sarasota, FL.
What fiscal year end does Oragenics Inc. observe?
Oragenics Inc.'s fiscal year ends on 1231.
Filing Stats: 4,518 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2024-08-09 16:30:43
Filing Documents
- form10-q.htm (10-Q) — 678KB
- ex10-1.htm (EX-10.1) — 288KB
- ex31-1.htm (EX-31.1) — 12KB
- ex31-2.htm (EX-31.2) — 13KB
- ex32-1.htm (EX-32.1) — 8KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001493152-24-031000.txt ( ) — 3344KB
- ogen-20240630.xsd (EX-101.SCH) — 25KB
- ogen-20240630_cal.xml (EX-101.CAL) — 34KB
- ogen-20240630_def.xml (EX-101.DEF) — 72KB
- ogen-20240630_lab.xml (EX-101.LAB) — 222KB
- ogen-20240630_pre.xml (EX-101.PRE) — 159KB
- form10-q_htm.xml (XML) — 303KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION 3 Item 1.
Financial Statements
Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 3 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Changes in Shareholders' Equity for the three and six months ended June 30, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk. 23 Item 4.
Controls and Procedures
Controls and Procedures 23
– OTHER INFORMATION
PART II – OTHER INFORMATION 24 Item 1.
Legal Proceedings
Legal Proceedings 24 Item 1A.
Risk Factors
Risk Factors 24 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 26
Signatures
Signatures 29 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL Oragenics, Inc. Condensed Consolidated Balance Sheets June 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 1,348,621 $ 3,483,501 Prepaid expenses and other current assets 270,334 382,273 Total current assets 1,618,955 3,865,774 Prepaid research and development expense 1,090,750 1,090,750 Operating lease right-of-use assets — 9,811 Total assets $ 2,709,705 $ 4,966,335 Liabilities and Shareholders' Equity Current liabilities: Accounts payable and accrued expenses $ 1,383,309 $ 1,475,667 Short-term notes payable — 312,703 Operating lease liabilities - Current — 9,811 Total liabilities 1,383,309 1,798,181 Shareholders' equity: Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, - 0 - and - 0 - Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at June 30, 2024 and December 31, 2023, respectively 1,592,723 1,592,723 Common stock, $ 0.001 par value; 350,000,000 shares authorized and 5,580,693 and 3,080,693 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 5,581 3,081 Additional paid-in capital 210,702,269 207,790,604 Accumulated Deficit ( 210,974,177 ) ( 206,218,254 ) Total shareholders' equity 1,326,396 3,168,154 Total liabilities and shareholders' equity $ 2,709,705 $ 4,966,335 The accompanying notes to the condensed consolidated financial statements are an integral part of these statements. 3 Oragenics, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 2024 2023 For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) Grant revenue $ — $ 13,163 $ — $ 30,187 Operating expenses: Research and development